Form 4: Longeveron General Counsel Awarded Significant Equity Compensation

Paul T. Lehr, General Counsel and Secretary of Longeveron Inc., has been granted 102,000 Restricted Stock Units and 34,000 stock options, increasing his beneficial ownership.

Summary

• Paul T. Lehr, the General Counsel and Secretary of Longeveron Inc. (LGVN), was granted equity awards on July 15, 2025.
• The awards include 102,000 Class A Common Stock in the form of time-based vesting Restricted Stock Units (RSUs).
• Additionally, 34,000 stock options were granted, with an exercise price of $1.47 per share.
• The stock options will vest quarterly over a three-year period, commencing on October 1, 2025, and expire on July 15, 2035.
• Following these transactions, Paul T. Lehr beneficially owns 356,073 shares of Class A Common Stock, which includes RSUs subject to future vesting, and 34,000 stock options.

Sentiment

Score: 7

Explanation: The grant of equity to a key executive is generally a positive sign of alignment and retention, but it is a routine compensation event rather than a major operational or financial announcement that would significantly alter the company's outlook.

Positives

• The grant of equity awards to a key executive like the General Counsel aligns management's long-term interests with those of shareholders, fostering a shared incentive for company performance.
• Significant equity compensation can serve as a strong retention tool for key personnel, ensuring continuity in leadership and strategic direction.

Risks

• The value of the granted Restricted Stock Units and stock options is contingent on the future performance of Longeveron Inc.'s stock price.
• The full benefit of the equity awards is subject to vesting schedules, meaning the executive must remain with the company for a specified period to realize the full value.

Future Outlook

The vesting schedule for the stock options, extending quarterly over three years from October 1, 2025, indicates a long-term commitment and incentive structure for the executive, aligning their future performance with the company's success.

Industry Context

Equity compensation, such as Restricted Stock Units and stock options, is a standard and widely adopted practice within the biotechnology and life sciences industry. It is crucial for attracting, retaining, and motivating key executives and scientific talent, aligning their financial incentives with the long-term growth and innovation goals typical of this sector.

Comparison to Industry Standards

• This Form 4 filing, detailing an equity grant to an executive, does not provide sufficient context or specific benchmarks to assess the compensation package against industry standards for comparable roles in similar biotech companies. Equity compensation structures vary significantly based on company stage, market capitalization, executive experience, and overall compensation philosophy.

Related Party Transactions

• The equity awards granted to Paul T. Lehr, an officer of Longeveron Inc., constitute a related party transaction as it involves compensation provided by the company to a key management personnel. This is a standard form of executive compensation.

Stakeholder Impact

• Shareholders: The equity grant aims to align the General Counsel's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Management: The General Counsel receives significant long-term incentive compensation, which can enhance motivation and retention.

Next Steps

• Continued vesting of the 102,000 Restricted Stock Units based on their time-based schedule.
• Quarterly vesting of the 34,000 stock options will commence on October 1, 2025, over a three-year period.
• Potential future exercise of the stock options by Paul T. Lehr, subject to vesting and market conditions, before their expiration on July 15, 2035.

Key Dates

Keywords

Longeveron Inc., LGVN, Paul T. Lehr, SEC Form 4, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, Corporate Governance